The Metropolitan Manila Development Authority (MMDA) started the vaccination of its employees who are medical frontliners, senior citizens, and persons with comorbidities to protect them from COVID-19.
200 personnel belonging to the A1, A2, and A3 on the priority of IATF were given their initial dose of the Sinovac COVID-19 vaccines.
“Senior citizens and medical frontliners are first to be inoculated.”
“We shall follow the priority list of the vaccination. Senior citizens and medical frontliners are first to be inoculated,” said MMDA Chairman Benhur Abalos.
According to Abalos, the MMDA has recorded 771 COVID-19 cases, 100 active cases while eight have already died. The agency has more than 8,000 employees.
“The MMDA sought the assistance of the Department of Health to have its frontliners, particularly those assigned in the field, inoculated.”
“Medical frontliners, including doctors and nurses, have the highest exposure to COVID-19 and are the most at risk of contracting the disease,” said Abalos, citing that the MMDA requested the Department of Health, to have its frontliners, particularly those assigned in the field, inoculated.
Since the COVID-19 pandemic began, the MMDA played a wider role, assisting the government in curbing the spread of the disease on top of its mandates.
“The MMDA houses the One Hospital Command Center, we coordinate actions with the Metro Manila mayors and the national government,” Abalos said.
As part of its preparations for the vaccination rollout, the MMDA’s isolation facility was converted into a vaccination area.
The agency also continues to implement basic health protocols such as wearing of face shield and face masks, maintaining physical distancing, and checking of body temperatures.
Marshalls are also in place at the MMDA building to make sure that all the health protocols are being followed.
The Inter-Agency Task Force for the Management of Emerging Infectious Diseases, through the DOH has identified medical frontliners, senior citizens aged 60 and above, and individuals aged 18-59 with co-morbidities, such as hypertension, diabetes, chronic respiratory disease, and immunodeficiency state, as priority groups for the vaccination.